Compare GPMT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | ONCY |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 106.1M |
| IPO Year | 2017 | 1999 |
| Metric | GPMT | ONCY |
|---|---|---|
| Price | $2.67 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.13 | ★ $6.00 |
| AVG Volume (30 Days) | 139.4K | ★ 695.5K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.33 |
| 52 Week High | $3.45 | $1.51 |
| Indicator | GPMT | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 46.86 |
| Support Level | $2.73 | $0.94 |
| Resistance Level | $2.82 | $1.01 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 40.00 | 69.83 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.